Abstract 43P
Background
Lenvatinib with PD-1 inhibitors showed promising efficacy in treating unresectable hepatocellular carcinoma (uHCC) but predicting treatment response (TR) remains challenging due to tumor heterogeneity. We aimed to develop models based on clinical and radiomics features using machine learning (ML) algorithms to predict the efficacy of lenvatinib (LEN) combined with tislelizumab (TIS) based therapy in uHCC patients (pts).
Methods
110 uHCC pts treated with LEN combined with TIS based therapy between 2019 and 2024 were recruited. Among them, 30 pts received LEN plus TIS, while 80 received the combination of LEN, TIS, and TACE. Clinical data and contrast-enhanced CT images were collected. TR was assessed by mRECIST. Five machine learning algorithms, including logistic regression, random forest (RF), neural networks, support vector machines and naive Bayes, were applied to develop prediction models based on clinical and radiomic features. The predictive performance of these models was evaluated using ROC curves, accuracy (ACC), calibration curves (CC), and decision curve analysis (DCA).
Results
Of 110 eligible pts, ORR was 33.6% with all partial response, and DCR was 75.9%. The cohort was randomly divided into a training set of 88 pts and a validation set of 22 pts. A total of 240 radiomic features were extracted, and the top 15 significant features were selected using the mRMR algorithm for further analysis. Prediction models based on 20 clinical variables and 15 radiomic features were developed using five different machine learning algorithms. The RF model showed the best predictive performance, with average area under the curve (AUC) of 0.99 and 0.72, and ACC values of 0.99 and 0.66 for the training and validation sets, respectively. CC and DCA further demonstrated the robust performance of the RF model in predicting treatment response.
Conclusions
Machine learning models based on clinical and radiomics features were successfully constructed to predict the efficacy of LEN and TIS based therapy in uHCC pts. These models offer potential guidance for personalized treatment strategies.
Clinical trial identification
NCT05543304.
Legal entity responsible for the study
The First Affiliated Hospital of Wenzhou Medical University.
Funding
Zhejiang Provincial Health Commission (WKJ-ZJ-2438).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract